肿瘤抑制因子控制 ULBP2，一种淋巴细胞免疫受体 NKG2D 的先天表面配体。
Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D.
机构信息
Department of Dermatology; University Hospital Essen; Essen, Germany.
出版信息
Oncoimmunology. 2012 Jul 1;1(4):535-536. doi: 10.4161/onci.19406.
Abstract
The activating receptor NKG2D, expressed on different innate and adaptive cytotoxic lymphocytes, has been demonstrated to play an important role in anti-tumor immunity. Now evidence is provided that tumor suppressors control expression of its ligand ULBP2 supporting the role of this receptor-ligand system as an innate barrier against tumor development.
摘要
激活受体 NKG2D 表达于不同的先天和适应性细胞毒性淋巴细胞上，已被证明在抗肿瘤免疫中发挥重要作用。现在有证据表明，肿瘤抑制因子控制其配体 ULBP2 的表达，支持该受体-配体系统作为先天屏障防止肿瘤发展的作用。
Zotero 插件